Stephen Seid, Purdue's former director of national accounts, explains during a deposition in 2018 the way his company interpreted declines in OxyContin sales when Purdue made the drug harder to crush and snort.
Stephen Seid, Purdue's former director of national accounts, explains during a deposition in 2018 the way his company interpreted declines in OxyContin sales when Purdue made the drug harder to crush and snort.